Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers [Phase 1, Phase 2]
Phase I/IIa clinical trial update for BR1733 in advanced cancers, including follicular lymphoma, peripheral T-cell lymphoma, and diffuse lar…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.
-
CLINICAL_TRIALS research · 2024-07-30Clinical Trial Update: Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A [Phase 1]
This clinical trial update describes a Phase 1 study of combining nivolumab with rituximab as first-line therapy for follicular lymphoma (gr…
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR [Phase 1, Phase 2]
A Phase 1/2 clinical trial at University Hospital Heidelberg is evaluating third-generation CD19-directed CAR T cells in relapsed or refract…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma [Phase 1, Phase 2]
This entry reports an ongoing Phase 1/2 clinical trial evaluating a triple-drug regimen of lenalidomide, venetoclax, and obinutuzumab in tre…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating Imvotamab monotherapy and in combination for relapsed/refractory non-Hodgkin lymphoma has been terminated…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL [Phase 1, Phase 2]
Mustang Bio's MB-106 study in relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia has been terminated, covering Phase 1…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up update on patients previously treated with Mustang Bio's CAR-T cell investigational product; the trial has been termin…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS research · 2024-07-18Clinical Trial Update: Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma [Phase 2]
This clinical trial update reports a Phase 2 study evaluating a combination of zanubrutinib, rituximab, and venetoclax in previously untreat…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma [NA]
This document provides an update on a clinical trial evaluating whole-body diffusion-weighted MRI for staging and predicting treatment respo…
-
EMA withdrawal · 2024-07-10EMA Lapsed: Zevalin (ibritumomab tiuxetan) — Ceft Biopharma s.r.o.
The EMA indicates Zevalin (ibritumomab tiuxetan) marketing authorization in the EU has lapsed. The MAH is Ceft Biopharma s.r.o., and the the…
-
CLINICAL_TRIALS withdrawal · 2024-07-08Clinical Trial Update: GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma [Phase 1, Phase 2]
The GEMHDM2014 trial evaluating Gem-HDM HDT and autologous stem cell transplant for relapsed/refractory lymphoma has been terminated after P…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) [Phase 1]
Phase 1 study evaluating safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS research · 2024-06-25Clinical Trial Update: Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating zanubrutinib in combination with G-CHOP for untreated intermediate-high risk follicular lymphoma; study st…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]
Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.
-
CLINICAL_TRIALS trial_result · 2024-06-05Clinical Trial Update: IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial update on IBI376 in relapsed or refractory follicular lymphoma and marginal zone lymphoma. The study status is comple…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy [NA]
A completed clinical trial evaluating the feasibility of a digital health coaching program for individuals after CAR T-cell therapy.
-
CLINICAL_TRIALS research · 2024-05-23Clinical Trial Update: BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.
This clinical trial update discusses the implications of BCL6 rearrangements across non-Hodgkin lymphomas, including follicular lymphoma, ma…
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of ibrutinib and venetoclax in relapsed or refractory follicular lymphoma has completed enrollmen…
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma [Phase 1, Phase 2]
A Phase 1/2 dose-finding and efficacy study of a triplet therapy (venetoclax, CC-486, and obinutuzumab) in follicular lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2024-05-09Clinical Trial Update: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 clinical trial evaluating rituximab in patients with newly diagnosed stage II, stage III, or stage IV follicular lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma [Phase 2]
Phase 2 trial comparing obinutuzumab plus zanubrutinib versus obinutuzumab alone in relapsed/refractory follicular lymphoma; the study has c…
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]
A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…